Current management of Parkinson's disease
- PMID: 20587924
- DOI: 10.4103/1596-3519.64743
Current management of Parkinson's disease
Abstract
Although Parkinson's disease (PD) is still incurable, a large number of different treatments have become available to improve the quality of life and physical and psychological morbidity, and its early treatment is of prime importance. This article reviews the current situation of PD. This review was based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications. The subject headings and keywords used were Parkinson's disease and therapeutic advances. Only articles written in English were included.The management of PD has evolved rapidly over the last 10 years with the advent of new drugs and new classes of drugs, but the currently available treatment methods are all symptomatic ones. However, some of these may have marginal disease-modifying effects. Progress in manufacture of newer drugs has markedly improved the treatment of early PD; however, the management of advanced Parkinson's symptoms remains a challenge. Currently no treatment has been proven to slow the progression of PD. Although symptomatic therapy can provide benefit for many years, PD will eventually result in significant morbidity.
Similar articles
-
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021. Clin Ther. 2007. PMID: 18035186 Review.
-
[Current pharmacotherapy of Parkinson's disease].Orv Hetil. 2000 Mar 5;141(10):483-8. Orv Hetil. 2000. PMID: 10750400 Review. Hungarian.
-
A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.Clin Ther. 2005 Nov;27(11):1710-24. doi: 10.1016/j.clinthera.2005.11.016. Clin Ther. 2005. PMID: 16368444 Review.
-
Levodopa in Parkinson's disease: from the past to the future.Expert Opin Pharmacother. 2010 Mar;11(4):627-35. doi: 10.1517/14656561003598919. Expert Opin Pharmacother. 2010. PMID: 20163273 Review.
-
Dopamine agonist-based strategies in the treatment of Parkinson's disease.Neurol Sci. 2008 Dec;29 Suppl 5:S371-4. doi: 10.1007/s10072-008-1049-4. Neurol Sci. 2008. PMID: 19381765 Review.
Cited by
-
A synthetic five amino acid propeptide increases dopamine neuron differentiation and neurochemical function.Neuropeptides. 2013 Feb;47(1):43-9. doi: 10.1016/j.npep.2012.08.004. Epub 2012 Sep 13. Neuropeptides. 2013. PMID: 22981157 Free PMC article.
-
Post-Treatment with Erinacine A, a Derived Diterpenoid of H. erinaceus, Attenuates Neurotoxicity in MPTP Model of Parkinson's Disease.Antioxidants (Basel). 2020 Feb 4;9(2):137. doi: 10.3390/antiox9020137. Antioxidants (Basel). 2020. PMID: 32033220 Free PMC article.
-
Therapeutic applications of antibodies in non-infectious neurodegenerative diseases.N Biotechnol. 2011 Sep;28(5):511-7. doi: 10.1016/j.nbt.2011.03.020. Epub 2011 Apr 5. N Biotechnol. 2011. PMID: 21473943 Free PMC article. Review.
-
Taurine protects dopaminergic neurons in a mouse Parkinson's disease model through inhibition of microglial M1 polarization.Cell Death Dis. 2018 Apr 1;9(4):435. doi: 10.1038/s41419-018-0468-2. Cell Death Dis. 2018. PMID: 29568078 Free PMC article.
-
Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation.J Mater Sci Mater Med. 2013 Sep;24(9):2101-15. doi: 10.1007/s10856-013-4965-7. Epub 2013 Jun 1. J Mater Sci Mater Med. 2013. PMID: 23728521
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical